Isocitrate dehydrogenase mutations in defining the biology of and supporting clinical decision making in glioblastoma

Ferenc Kálovits, Márton Tompa, Ádám Nagy, B. Kálmán

Research output: Contribution to journalArticle

Abstract

Background and purpose - Oncogenesis is related to a sequential accumulation of somatic mutations. Comprehensive characterizations of the genomic landscapes have been completed recently for several tumors, glioblastoma being among the first ones. Our own transla- tional research studies have been focused on defining molecular subtypes of glioblastoma in the clinical setting because of an expected prognostic and therapeutic utility of the information. Somatic mutations in genes of the isocitrate dehydrogenase (IDH) enzyme family appear to be among the best-defined biomarkers that also influence tumor behavior and confer clinical utility. Methods - We have reviewed the literature including our own results to summarize basic science and clinical correlates of IDH mutations. Results - The surveyed data reveal genomic, transcriptom- ic, epigenomic and biochemical consequences of IDH mutations in the context of glioblastoma biology and phe- notype. In addition, a few studies highlight the therapeutic potential of targeting IDH, although thus far all tests have only been conducted in the preclinical setting. Conclusions - Somatic mutations in isoforms of IDH genes represent important biomarkers that correlate with biochemical, biological and phenotypic features of glioblastoma, and may also facilitate the development of new therapeutic strategies complementing the currently available approved protocols.

Original languageEnglish
Pages (from-to)237-247
Number of pages11
JournalIdeggyogyaszati Szemle
Volume71
Issue number7-8
DOIs
Publication statusPublished - Jul 30 2018

Fingerprint

Isocitrate Dehydrogenase
Glioblastoma
Mutation
Biomarkers
Translational Medical Research
Epigenomics
Genes
Neoplasms
Protein Isoforms
Carcinogenesis
Therapeutics
Clinical Decision-Making
Phenotype
Enzymes

Keywords

  • Biochemistry
  • Glioblastoma
  • Isocitrate dehydrogenase
  • Somatic mutations
  • Therapy

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

Isocitrate dehydrogenase mutations in defining the biology of and supporting clinical decision making in glioblastoma. / Kálovits, Ferenc; Tompa, Márton; Nagy, Ádám; Kálmán, B.

In: Ideggyogyaszati Szemle, Vol. 71, No. 7-8, 30.07.2018, p. 237-247.

Research output: Contribution to journalArticle

@article{2d31644632b44824868d2ec25cd3721a,
title = "Isocitrate dehydrogenase mutations in defining the biology of and supporting clinical decision making in glioblastoma",
abstract = "Background and purpose - Oncogenesis is related to a sequential accumulation of somatic mutations. Comprehensive characterizations of the genomic landscapes have been completed recently for several tumors, glioblastoma being among the first ones. Our own transla- tional research studies have been focused on defining molecular subtypes of glioblastoma in the clinical setting because of an expected prognostic and therapeutic utility of the information. Somatic mutations in genes of the isocitrate dehydrogenase (IDH) enzyme family appear to be among the best-defined biomarkers that also influence tumor behavior and confer clinical utility. Methods - We have reviewed the literature including our own results to summarize basic science and clinical correlates of IDH mutations. Results - The surveyed data reveal genomic, transcriptom- ic, epigenomic and biochemical consequences of IDH mutations in the context of glioblastoma biology and phe- notype. In addition, a few studies highlight the therapeutic potential of targeting IDH, although thus far all tests have only been conducted in the preclinical setting. Conclusions - Somatic mutations in isoforms of IDH genes represent important biomarkers that correlate with biochemical, biological and phenotypic features of glioblastoma, and may also facilitate the development of new therapeutic strategies complementing the currently available approved protocols.",
keywords = "Biochemistry, Glioblastoma, Isocitrate dehydrogenase, Somatic mutations, Therapy",
author = "Ferenc K{\'a}lovits and M{\'a}rton Tompa and {\'A}d{\'a}m Nagy and B. K{\'a}lm{\'a}n",
year = "2018",
month = "7",
day = "30",
doi = "10.18071/isz.71.0237",
language = "English",
volume = "71",
pages = "237--247",
journal = "Ideggyogyaszati Szemle",
issn = "0019-1442",
publisher = "Ifjusagi Lap-es Konyvkiado Vallalat",
number = "7-8",

}

TY - JOUR

T1 - Isocitrate dehydrogenase mutations in defining the biology of and supporting clinical decision making in glioblastoma

AU - Kálovits, Ferenc

AU - Tompa, Márton

AU - Nagy, Ádám

AU - Kálmán, B.

PY - 2018/7/30

Y1 - 2018/7/30

N2 - Background and purpose - Oncogenesis is related to a sequential accumulation of somatic mutations. Comprehensive characterizations of the genomic landscapes have been completed recently for several tumors, glioblastoma being among the first ones. Our own transla- tional research studies have been focused on defining molecular subtypes of glioblastoma in the clinical setting because of an expected prognostic and therapeutic utility of the information. Somatic mutations in genes of the isocitrate dehydrogenase (IDH) enzyme family appear to be among the best-defined biomarkers that also influence tumor behavior and confer clinical utility. Methods - We have reviewed the literature including our own results to summarize basic science and clinical correlates of IDH mutations. Results - The surveyed data reveal genomic, transcriptom- ic, epigenomic and biochemical consequences of IDH mutations in the context of glioblastoma biology and phe- notype. In addition, a few studies highlight the therapeutic potential of targeting IDH, although thus far all tests have only been conducted in the preclinical setting. Conclusions - Somatic mutations in isoforms of IDH genes represent important biomarkers that correlate with biochemical, biological and phenotypic features of glioblastoma, and may also facilitate the development of new therapeutic strategies complementing the currently available approved protocols.

AB - Background and purpose - Oncogenesis is related to a sequential accumulation of somatic mutations. Comprehensive characterizations of the genomic landscapes have been completed recently for several tumors, glioblastoma being among the first ones. Our own transla- tional research studies have been focused on defining molecular subtypes of glioblastoma in the clinical setting because of an expected prognostic and therapeutic utility of the information. Somatic mutations in genes of the isocitrate dehydrogenase (IDH) enzyme family appear to be among the best-defined biomarkers that also influence tumor behavior and confer clinical utility. Methods - We have reviewed the literature including our own results to summarize basic science and clinical correlates of IDH mutations. Results - The surveyed data reveal genomic, transcriptom- ic, epigenomic and biochemical consequences of IDH mutations in the context of glioblastoma biology and phe- notype. In addition, a few studies highlight the therapeutic potential of targeting IDH, although thus far all tests have only been conducted in the preclinical setting. Conclusions - Somatic mutations in isoforms of IDH genes represent important biomarkers that correlate with biochemical, biological and phenotypic features of glioblastoma, and may also facilitate the development of new therapeutic strategies complementing the currently available approved protocols.

KW - Biochemistry

KW - Glioblastoma

KW - Isocitrate dehydrogenase

KW - Somatic mutations

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=85051983612&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85051983612&partnerID=8YFLogxK

U2 - 10.18071/isz.71.0237

DO - 10.18071/isz.71.0237

M3 - Article

VL - 71

SP - 237

EP - 247

JO - Ideggyogyaszati Szemle

JF - Ideggyogyaszati Szemle

SN - 0019-1442

IS - 7-8

ER -